Based on the ProShares Ultra Nasdaq Biotechnology stock forecast from 0 analysts, the average analyst target price for ProShares Ultra Nasdaq Biotechnology is not available over the next 12 months. ProShares Ultra Nasdaq Biotechnology’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of ProShares Ultra Nasdaq Biotechnology is Slightly Bearish, which is based on 2 positive signals and 4 negative signals. At the last closing, ProShares Ultra Nasdaq Biotechnology’s stock price was USD 52.14. ProShares Ultra Nasdaq Biotechnology’s stock price has changed by +1.56% over the past week, -11.67% over the past month and -14.79% over the last year.
No recent analyst target price found for ProShares Ultra Nasdaq Biotechnology
No recent average analyst rating found for ProShares Ultra Nasdaq Biotechnology
Company Overview ProShares Ultra Nasdaq Biotechnology
The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the Daily Target. The index is a modified capitalization weighted index that includes securities of Nasdaq listed companies that are classified as either biotechnology or pharmaceutical. The fund is non-diversified. Read Less
The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the Daily Target. The index is a modified capitalization weighted index that includes securities of Nasdaq listed companies that are classified ...Read More
Frequently Asked Questions About ProShares Ultra Nasdaq Biotechnology (BIB) Stock
Stock Target Advisor's fundamental analysis for ProShares Ultra Nasdaq Biotechnology's stock is Slightly Bearish.
BIB stock's dividend yield is 0.83%.
Our analysis grades BIB stock's dividend yield at F. This means that BIB stock's dividend yield is above 50% of the stocks in the Trading--Leveraged Equity sector in the NSD exchange.
Based on this BIB may be a average dividend stock for its sector.
Unfortunately we do not have enough data on BIB's stock to indicate what its average analyst target is.
BIB stock's Price/Earning ratio is 20.40.
Our analysis grades BIB stock's Price / Earning ratio at A+. This means that BIB stock's Price/Earning ratio is above 0% of the stocks in the Trading--Leveraged Equity sector in the NSD exchange.
Based on this BIB may be undervalued for its sector.
The last closing price of BIB's stock was USD 52.14.
The most recent market capitalization for BIB is USD 0.06B.
Unfortunately we do not have enough analyst data on BIB's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains ProShares Ultra Nasdaq Biotechnology's stock.
Sorry, we do not have any data on the number of employees for ProShares Ultra Nasdaq Biotechnology.
Sorry we do not have any infomation available on ProShares Ultra Nasdaq Biotechnology's address.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Underpriced compared to earnings
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Below median total returns
The company has under performed its peers on annual average total returns in the past 5 years.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Frequently Asked Questions About ProShares Ultra Nasdaq Biotechnology (BIB) Stock
Stock Target Advisor's fundamental analysis for ProShares Ultra Nasdaq Biotechnology's stock is Slightly Bearish.
BIB stock's dividend yield is 0.83%.
Our analysis grades BIB stock's dividend yield at F. This means that BIB stock's dividend yield is above 50% of the stocks in the Trading--Leveraged Equity sector in the NSD exchange.
Based on this BIB may be a average dividend stock for its sector.
Unfortunately we do not have enough data on BIB's stock to indicate what its average analyst target is.
BIB stock's Price/Earning ratio is 20.40.
Our analysis grades BIB stock's Price / Earning ratio at A+. This means that BIB stock's Price/Earning ratio is above 0% of the stocks in the Trading--Leveraged Equity sector in the NSD exchange.
Based on this BIB may be undervalued for its sector.
The last closing price of BIB's stock was USD 52.14.
The most recent market capitalization for BIB is USD 0.06B.
Unfortunately we do not have enough analyst data on BIB's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains ProShares Ultra Nasdaq Biotechnology's stock.
Sorry, we do not have any data on the number of employees for ProShares Ultra Nasdaq Biotechnology.
Sorry we do not have any infomation available on ProShares Ultra Nasdaq Biotechnology's address.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for BIB !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
